This study was performed to evaluate the impact of Alan Balmer’s Life Force energy transmissions on vitamin D3 and DMEM medium on bone health. DMEM is a modification of Basal Medium Eagle (BME) that contains a four-fold higher concentration of amino acids and vitamins, as well as additional supplementary components. Serum, like DMEM, is used in cell culture because it provides a wide variety of macromolecular proteins, low molecular weight nutrients, carrier proteins for water – insoluble components, and other compounds necessary for in vitro growth of cells, such as hormones and attachment factors.
The test components, vitamin D3 and DMEM, were divided into two parts. One part of each sample received the treatment by Alan Balmer and those samples were labeled TET (Trivedi Effect Treated), while the other parts of each sample were labeled UT (untreated test).
Alkaline Phosphatase (ALP), collagen synthesis, and bone mineralization assessment testing was performed to assess bone health in human bone osteosarcoma cells.
Alkaline Phosphatase (ALP) and calcium levels in post-menopausal women are the main two vital biochemical markers of bone metabolism. Bone-specific ALP is the most important marker for osteoblast differentiation. Further, it is generally accepted that an increased calcium intake along with an adequate source of vitamin D is important for maintaining good bone health. Vitamin D also plays an important role in maintaining an adequate level of serum calcium and phosphorus. Therefore, vitamin D has a great impact in forming and maintaining strong bones. Bone strength depends on the quality, geometry, shape, microarchitecture turnover, mineral content, and the collagen content.
The results of the ALP testing revealed the sample where the treated vitamin D3 and the untreated DMEM test yielded a significant increase by 317.97% over the untreated group measured at 10 ug/ml. (or micrograms per milliliter).
Upon reversing the treatment of the two part sample items, the results of the ALP testing where the sample consisted of untreated vitamin D3 and treated DMEM yielded an increase of 245.94% over the untreated group, also measured at 10 ug/ml. (or micrograms per milliliter).
The ALP testing where the sample consisted of both the treated vitamin D3 and DMEM yielded an increase of 247.97% over the untreated group, again measured at 10 ug/ml.
In addition to the above testing, both the combined treated samples of vitamin D3 and DMEM were also applied using the measurements of 0.1 ug/ml. and 1 ug/ml, yielding increases of 252.87% and 244.05% over the untreated group.
Finally, using the measured result of 100 ug/ml., the untreated DMEM and treated vitamin D3 yielded an increase of 149.41% and the (TET) treated DMEM and vitamin D3 yielded an increase of 175.17% compared to the untreated group.
Collagen is the major structural protein responsible for bone calcification. In the aging state, the mechanical properties of the bones becomes impaired and the bones get fragile, that causes various clinical disorders associated with bone collagen abnormalities and bone fragility, such as osteogenesis imperfecta and osteoporosis.
Applying similar testing procedures to collagen revealed the following performance levels compared to the untreated group.
The collagen level actually increased 607.3% over the untreated group when the untreated DMEM and treated vitamin D3 test item was measured.
When the sample was reversed, and the untreated vitamin D3 test item and the treated DMEM was measured, the increase measured 346.41% improvement over the untreated group.
When both the vitamin D3 and the DMEM items were both treated together, the increase measured 197.61%.
All three of the above tests were performed at .01 ug/ml. (or micrograms per milliliter) compared to the untreated group.
When these three tests were performed at 100 ug/ml., the results yielded 31.98% for untreated DMEM/ treated vitamin D3, 54.87% for untreated vitamin D3/ treated DMEM and 67.1% in the case where the treatment was applied both to the DMEM and vitamin D3 item.
In the bone mineralization activity, the level increased 71.41% over the untreated group when the Trivedi Effect treatment was applied to the vitamin D3 and the DMEM was untreated.
When the DMEM was treated with the treatment and the vitamin D3 was untreated, the increase measured 199.92% over the untreated group.
Finally, when both the DMEM and vitamin D3 were treated by the treatment, the increase measured 32.60% over the untreated group.
These three bone mineralization tests were applied at .01 ug/ml.
Finally, at test applied using 50 ug/ml. was applied to an untreated DMEM group and treated vitamin D3 group and also a Trivedi Effect treated DMEM group and untreated vitamin D3 group, yielding the increased results of 28.29% and 25.59%.
Overall, the treated vitamin D3 was significantly improved from the bone health parameters and could be a powerful alternative nutraceutical supplement to combat vitamin D3 deficiency. This alternative could become a significant ally in the fight against various bone related problems, including rickets, osteomalacia, osteoporosis, low bone density, bone stress management and prevention, autoimmune and inflammatory diseases, and anti-aging by improving overall health.